CA2956208C - METHODS FOR DETERMINING TISSUES AND/OR CELL TYPES RENDERING CELL-FREE DNA AND RELATED METHODS FOR DETERMINING A DISEASE OR DISORDER - Google Patents

METHODS FOR DETERMINING TISSUES AND/OR CELL TYPES RENDERING CELL-FREE DNA AND RELATED METHODS FOR DETERMINING A DISEASE OR DISORDER

Info

Publication number
CA2956208C
CA2956208C CA2956208A CA2956208A CA2956208C CA 2956208 C CA2956208 C CA 2956208C CA 2956208 A CA2956208 A CA 2956208A CA 2956208 A CA2956208 A CA 2956208A CA 2956208 C CA2956208 C CA 2956208C
Authority
CA
Canada
Prior art keywords
cfdna
tissue
cell
nucleosome
map
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2956208A
Other languages
English (en)
French (fr)
Other versions
CA2956208A1 (en
Inventor
Jay Shendure
Matthew Snyder
Martin Kircher
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CA2956208A1 publication Critical patent/CA2956208A1/en
Application granted granted Critical
Publication of CA2956208C publication Critical patent/CA2956208C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B45/00—ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Cell Biology (AREA)
  • Primary Health Care (AREA)
  • Signal Processing (AREA)
  • Hospice & Palliative Care (AREA)
CA2956208A 2014-07-25 2015-07-27 METHODS FOR DETERMINING TISSUES AND/OR CELL TYPES RENDERING CELL-FREE DNA AND RELATED METHODS FOR DETERMINING A DISEASE OR DISORDER Active CA2956208C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462029178P 2014-07-25 2014-07-25
US62/029,178 2014-07-25
US201462087619P 2014-12-04 2014-12-04
US62/087,619 2014-12-04
PCT/US2015/042310 WO2016015058A2 (en) 2014-07-25 2015-07-27 Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same

Publications (2)

Publication Number Publication Date
CA2956208A1 CA2956208A1 (en) 2016-01-28
CA2956208C true CA2956208C (en) 2025-07-08

Family

ID=55163988

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2956208A Active CA2956208C (en) 2014-07-25 2015-07-27 METHODS FOR DETERMINING TISSUES AND/OR CELL TYPES RENDERING CELL-FREE DNA AND RELATED METHODS FOR DETERMINING A DISEASE OR DISORDER

Country Status (8)

Country Link
US (4) US20170211143A1 (enExample)
EP (2) EP4358097A1 (enExample)
JP (3) JP2017522908A (enExample)
KR (2) KR102696857B1 (enExample)
CN (2) CN107002122B (enExample)
AU (2) AU2015292311B2 (enExample)
CA (1) CA2956208C (enExample)
WO (1) WO2016015058A2 (enExample)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129363A2 (en) 2011-03-24 2012-09-27 President And Fellows Of Harvard College Single cell nucleic acid detection and analysis
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10041127B2 (en) 2012-09-04 2018-08-07 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
CN106062214B (zh) 2013-12-28 2020-06-09 夸登特健康公司 用于检测遗传变异的方法和系统
PT3543356T (pt) 2014-07-18 2021-10-04 Univ Hong Kong Chinese Análise dos padrões de metilação de tecidos em mistura de adn
KR102696857B1 (ko) 2014-07-25 2024-08-19 유니버시티 오브 워싱톤 무세포 dna를 생성하는 조직 및/또는 세포 유형을 결정하는 방법 및 이를 사용하여 질환 또는 장애를 확인하는 방법
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
WO2016123698A1 (en) * 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
AU2016218631B2 (en) 2015-02-10 2022-03-10 The Chinese University Of Hong Kong Detecting mutations for cancer screening and fetal analysis
ES2960201T3 (es) 2015-07-23 2024-03-01 Univ Hong Kong Chinese Análisis de los patrones de fragmentación del ADN acelular
CN108368548A (zh) * 2015-11-09 2018-08-03 普罗格尼迪公司 用于确定dna分子的来源的方法
JP2019507585A (ja) 2015-12-17 2019-03-22 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａの分析による腫瘍遺伝子コピー数を決定するための方法
US11514289B1 (en) 2016-03-09 2022-11-29 Freenome Holdings, Inc. Generating machine learning models using genetic data
JP7448310B2 (ja) * 2016-07-06 2024-03-12 ガーダント ヘルス， インコーポレイテッド セルフリー核酸のフラグメントームプロファイリングのための方法
JP7048105B2 (ja) 2016-07-15 2022-04-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 核酸ライブラリを生成する方法
WO2018027176A1 (en) 2016-08-05 2018-02-08 The Broad Institute, Inc. Methods for genome characterization
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
EP3792922A1 (en) 2016-09-30 2021-03-17 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
EP3526350B1 (en) * 2016-10-12 2025-07-16 Bellwether Bio, Inc. Determining cell type origin of circulating cell-free dna with molecular counting
IL265769B2 (en) 2016-10-19 2023-12-01 Univ Hong Kong Chinese Estimation of gestational age using methylation and size profile of maternal plasma DNA
SG11201903509QA (en) 2016-10-24 2019-05-30 Univ Hong Kong Chinese Methods and systems for tumor detection
CA3039685A1 (en) 2016-11-30 2018-06-07 The Chinese University Of Hong Kong Analysis of cell-free dna in urine and other samples
ES2983411T3 (es) * 2016-12-13 2024-10-23 Bellwether Bio Inc Determinación de un estado fisiológico en un individuo analizando los puntos finales de fragmentos de ADN libre de células en una muestra biológica
WO2018119452A2 (en) 2016-12-22 2018-06-28 Guardant Health, Inc. Methods and systems for analyzing nucleic acid molecules
US11821027B2 (en) 2017-01-10 2023-11-21 Juno Therapeutics, Inc. Epigenetic analysis of cell therapy and related methods
EP3574108B1 (en) 2017-01-25 2024-08-28 The Chinese University Of Hong Kong Diagnostic applications using nucleic acid fragments
CA3063627A1 (en) 2017-05-15 2018-11-22 Katholieke Universiteit Leuven Method for analysing cell-free nucleic acids
EP3635134A4 (en) * 2017-06-09 2021-03-03 Bellwether Bio, Inc. DIAGNOSTIC CANCER OR OTHER PHYSIOLOGICAL CONDITIONS USING CIRCULATING NUCLEIC ACID FRAGMENT SENTINEL END POINTS
EP3635133A4 (en) * 2017-06-09 2021-03-03 Bellwether Bio, Inc. DETERMINATION OF THE TYPE OF CANCER IN A SUBJECT BY PROBABILISTIC MODELING OF END POINTS OF CIRCULATING NUCLEIC ACID FRAGMENT
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
CN111051536A (zh) 2017-07-26 2020-04-21 香港中文大学 利用不含细胞的病毒核酸改善癌症筛选
WO2019075251A2 (en) * 2017-10-12 2019-04-18 Nantomics, Llc CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS
CN107545153B (zh) * 2017-10-25 2021-06-11 桂林电子科技大学 一种基于卷积神经网络的核小体分类预测方法
WO2019024341A1 (zh) 2017-11-27 2019-02-07 深圳华大生命科学研究院 一种体液游离dna的文库构建方法及其应用
CN108061794B (zh) * 2017-12-25 2020-03-27 苏州大学 一种无染色、无探针、无损检测细胞或类细胞结构微生物的类型及其周期的方法
US11584929B2 (en) 2018-01-12 2023-02-21 Claret Bioscience, Llc Methods and compositions for analyzing nucleic acid
US11781183B2 (en) * 2018-03-13 2023-10-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Diagnostic use of cell free DNA chromatin immunoprecipitation
AU2019249422B2 (en) 2018-04-02 2025-09-25 Grail, Inc. Methylation markers and targeted methylation probe panels
WO2019209884A1 (en) * 2018-04-23 2019-10-31 Grail, Inc. Methods and systems for screening for conditions
CN120608151A (zh) * 2018-05-18 2025-09-09 约翰·霍普金斯大学 用于评估和/或治疗癌症的无细胞dna
JP2021526791A (ja) * 2018-06-04 2021-10-11 ガーダント ヘルス， インコーポレイテッド セルフリー核酸の細胞起源を決定するための方法およびシステム
JP7537748B2 (ja) 2018-06-06 2024-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 核酸ライブラリを生成する方法ならびにそれを実施するための組成物およびキット
CN108796056A (zh) * 2018-06-28 2018-11-13 元码基因科技（北京）股份有限公司 基于游离dna的目标基因捕获技术进行组织溯源的方法
WO2020006369A1 (en) * 2018-06-29 2020-01-02 Guardant Health, Inc. Methods and systems for analysis of ctcf binding regions in cell-free dna
CN108913682A (zh) * 2018-07-05 2018-11-30 上海奥测医疗科技有限公司 一种制备cfDNA参考品的方法
WO2020020174A1 (en) * 2018-07-23 2020-01-30 The Chinese University Of Hong Kong Cell-free dna damage analysis and its clinical applications
CN109448783B (zh) * 2018-08-07 2022-05-13 清华大学 一种染色质拓扑结构域边界的分析方法
WO2020069350A1 (en) 2018-09-27 2020-04-02 Grail, Inc. Methylation markers and targeted methylation probe panel
CN112740239B (zh) * 2018-10-08 2025-02-28 福瑞诺姆控股公司 转录因子分析
CN111172263A (zh) * 2018-11-12 2020-05-19 北京医院 一种应用于无创产前检测的参考物质及其制备方法
CN113227468A (zh) * 2018-11-21 2021-08-06 卡里乌斯公司 感染性疾病的检测和预测
US20200199685A1 (en) 2018-12-17 2020-06-25 Guardant Health, Inc. Determination of a physiological condition with nucleic acid fragment endpoints
TWI868095B (zh) * 2018-12-19 2025-01-01 香港中文大學 游離dna末端特徵
US11657897B2 (en) * 2018-12-31 2023-05-23 Nvidia Corporation Denoising ATAC-seq data with deep learning
JP2022517456A (ja) * 2019-01-24 2022-03-09 イルミナ インコーポレイテッド 臓器健康および疾患をモニタリングするための方法およびシステム
JP7573536B2 (ja) 2019-01-31 2024-10-25 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａを単離するための組成物および方法
CN109841265B (zh) * 2019-02-22 2021-09-21 清华大学 使用片段化模式确定血浆游离核酸分子组织来源的方法和系统及应用
WO2020198942A1 (zh) * 2019-03-29 2020-10-08 中国科学技术大学 基于峰聚类的单细胞染色质可及性测序数据分析方法和系统
EP3976822A1 (en) 2019-05-31 2022-04-06 Guardant Health, Inc. Methods and systems for improving patient monitoring after surgery
CN110272985B (zh) * 2019-06-26 2021-08-17 广州市雄基生物信息技术有限公司 基于外周血血浆游离dna高通量测序技术的肿瘤筛查试剂盒及其系统与方法
US11891653B2 (en) 2019-09-30 2024-02-06 Guardant Health, Inc. Compositions and methods for analyzing cell-free DNA in methylation partitioning assays
CN110739027B (zh) * 2019-10-23 2023-04-18 深圳吉因加医学检验实验室 一种基于染色质区域覆盖深度的癌症组织定位方法及系统
ES3031713T3 (en) 2019-11-26 2025-07-10 Guardant Health Inc Methods, compositions and systems for improving the binding of methylated polynucleotides
WO2021121368A1 (en) * 2019-12-18 2021-06-24 The Chinese University Of Hong Kong Cell-free dna fragmentation and nucleases
CN115066500A (zh) * 2019-12-19 2022-09-16 新加坡科技研究局 估计循环肿瘤dna负荷的方法以及相关的试剂盒和方法
EP4077735A4 (en) * 2019-12-20 2024-01-24 AccuraGen Holdings Limited METHOD AND SYSTEMS FOR DETECTING DISEASES
EP4081655A1 (en) 2019-12-24 2022-11-02 Vib Vzw Disease detection in liquid biopsies
CA3162089A1 (en) * 2020-01-08 2021-07-15 Yuk-Ming Dennis Lo Biterminal dna fragment types in cell-free samples and uses thereof
US20230053409A1 (en) * 2020-01-09 2023-02-23 Seoul National University R&Db Foundation Atac-seq data normalization and method for utilizing same
CN111254194B (zh) * 2020-01-13 2021-09-07 东南大学 基于cfDNA的测序及数据分析的癌症相关生物标记及其在cfDNA样品分类中的应用
CN115428088A (zh) * 2020-02-13 2022-12-02 10X基因组学有限公司 用于基因表达和dna染色质可及性的联合交互式可视化的系统和方法
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
CN113362897A (zh) * 2020-03-06 2021-09-07 福建和瑞基因科技有限公司 基于核小体分布特征的肿瘤标志物筛选方法及应用
WO2021222828A1 (en) 2020-04-30 2021-11-04 Guardant Health, Inc. Methods for sequence determination using partitioned nucleic acids
EP4154255A4 (en) * 2020-05-22 2024-07-17 Aqtual, Inc. METHODS FOR CHARACTERIZING CELL-FREE NUCLEIC ACID FRAGMENTS
CN111724860B (zh) * 2020-06-18 2021-03-16 深圳吉因加医学检验实验室 一种基于测序数据识别染色质开放区域的方法及装置
EP4407042A3 (en) 2020-07-10 2024-09-18 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
CN111881418B (zh) * 2020-07-27 2023-05-16 中国农业科学院农业信息研究所 一种基于二分法的大豆气象产量预测方法及系统
EP4189111B1 (en) 2020-07-30 2025-02-19 Guardant Health, Inc. Methods for isolating cell-free dna
CN112085067B (zh) * 2020-08-17 2022-07-12 浙江大学 一种高通量筛选dna损伤反应抑制剂的方法
WO2022046947A1 (en) 2020-08-25 2022-03-03 Guardant Health, Inc. Methods and systems for predicting an origin of a variant
WO2022061080A1 (en) * 2020-09-17 2022-03-24 The Regents Of The University Of Colorado, A Body Corporate Signatures in cell-free dna to detect disease, track treatment response, and inform treatment decisions
CA3193090A1 (en) 2020-09-30 2022-04-07 Guardant Health, Inc. Methods and systems to improve the signal to noise ratio of dna methylation partitioning assays
WO2022087309A1 (en) 2020-10-23 2022-04-28 Guardant Health, Inc. Compositions and methods for analyzing dna using partitioning and base conversion
WO2022115810A1 (en) 2020-11-30 2022-06-02 Guardant Health, Inc. Compositions and methods for enriching methylated polynucleotides
WO2022140629A1 (en) 2020-12-23 2022-06-30 Guardant Health, Inc. Methods and systems for analyzing methylated polynucleotides
TW202242145A (zh) * 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
US20230175064A1 (en) * 2021-02-09 2023-06-08 Illumina, Inc. Methods and systems for monitoring organ health and disease
EP4291679B1 (en) 2021-02-12 2026-02-04 Guardant Health, Inc. Methods for detecting nucleic acid variants
WO2022204730A1 (en) 2021-03-25 2022-09-29 Guardant Health, Inc. Methods and compositions for quantifying immune cell dna
EP4320277A4 (en) * 2021-04-08 2025-03-05 Delfi Diagnostics, Inc. CANCER DETECTION METHOD USING GENOME-WIDE CELL-FREE DNA FRAGMENTATION PROFILES
WO2022217096A2 (en) * 2021-04-08 2022-10-13 Ha Gavin Cell-free dna sequence data analysis method to examine nucleosome protection and chromatin accessibility
JP2024523401A (ja) 2021-06-21 2024-06-28 ガーダント ヘルス， インコーポレイテッド コピー数情報に基づく組織起源分析のための方法および組成物
EP4409024A1 (en) 2021-09-30 2024-08-07 Guardant Health, Inc. Compositions and methods for synthesis and use of probes targeting nucleic acid rearrangements
CA3246524A1 (en) 2022-04-07 2023-10-12 Guardant Health, Inc. TUMOR PRESENCE DETECTION BASED ON THE METHYLATION STATE OF ACELLULAR NUCLEIC ACID MOLECULES
GB202205710D0 (en) 2022-04-19 2022-06-01 Univ Of Essex Enterprises Limited Cell-free DNA-based methods
EP4547857A1 (en) 2022-06-30 2025-05-07 Guardant Health, Inc. Enrichment of aberrantly methylated dna
WO2024056720A1 (en) 2022-09-13 2024-03-21 Medizinische Universität Graz Determining of health status and treatment monitoring with cell-free dna
JP2025532196A (ja) 2022-09-27 2025-09-29 ガーダント ヘルス， インコーポレイテッド 免疫細胞ｄｎａを定量するための方法
JP2025542260A (ja) 2022-12-22 2025-12-25 ガーダント ヘルス， インコーポレイテッド エラー補正を伴うメチル化保存増幅を含む方法
WO2024138180A2 (en) 2022-12-22 2024-06-27 Guardant Health, Inc. Integrated targeted and whole genome somatic and dna methylation sequencing workflows
WO2024233502A1 (en) 2023-05-05 2024-11-14 Guardant Health, Inc. Cell-free dna blood-based test for cancer screening
WO2025029475A1 (en) 2023-07-28 2025-02-06 Guardant Health, Inc. Methods to enrich nucleotide variants by negative selection
WO2025038399A1 (en) 2023-08-11 2025-02-20 Guardant Health, Inc. Methylated enrichment methods for single-molecule genetic and epigenetic sequencing
CN117230165A (zh) * 2023-09-01 2023-12-15 深圳湾实验室 一种无创产前检测胎儿染色体拷贝数异常的优化方法
WO2025064706A1 (en) 2023-09-19 2025-03-27 Guardant Health, Inc. Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules
WO2025076452A1 (en) 2023-10-06 2025-04-10 Guardant Health, Inc. Detecting tumor-related information based on methylation status of cell-free nucleic acid molecules
WO2025137389A2 (en) 2023-12-22 2025-06-26 Guardant Health, Inc. Methods for targeted single-molecule genetic and epigenetic sequencing
WO2025207817A1 (en) 2024-03-26 2025-10-02 Guardant Health, Inc. Method of determining the likelihood of a disease by combining biomarkers and imaging
WO2025208044A1 (en) 2024-03-28 2025-10-02 Guardant Health, Inc. Methods for cancer detection using molecular patterns
WO2025235889A1 (en) 2024-05-10 2025-11-13 Guardant Health, Inc. Methods involving multiplexed pooled pcr
WO2025250544A1 (en) 2024-05-31 2025-12-04 Guardant Health, Inc. Methods for analyzing chromatin architecture in tissue to boost detection of cancer associated signals in cell-free dna
WO2026015607A1 (en) 2024-07-09 2026-01-15 Guardant Health, Inc. Methods for partitioning hyper-, hypo-, and non-methylated dna

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016742D0 (en) * 2000-07-10 2000-08-30 Simeg Limited Diagnostic method
JP2002272497A (ja) 2001-03-15 2002-09-24 Venture Link Co Ltd 癌の診断方法、およびその診断用ベクター
US6927028B2 (en) 2001-08-31 2005-08-09 Chinese University Of Hong Kong Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA
AU2004217872B2 (en) 2003-03-05 2010-03-25 Genetic Technologies Limited Identification of fetal DNA and fetal cell markers in maternal plasma or serum
DE60328193D1 (de) 2003-10-16 2009-08-13 Sequenom Inc Nicht invasiver Nachweis fötaler genetischer Merkmale
US20070122823A1 (en) 2005-09-01 2007-05-31 Bianchi Diana W Amniotic fluid cell-free fetal DNA fragment size pattern for prenatal diagnosis
DK3002338T3 (da) 2006-02-02 2019-08-05 Univ Leland Stanford Junior Ikke-invasiv føtal genetisk screening ved digital analyse
EP2351858B1 (en) 2006-02-28 2014-12-31 University of Louisville Research Foundation Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
CN101153336B (zh) 2006-09-27 2011-09-07 香港中文大学 检测dna甲基化程度的方法和试剂盒
US7842482B2 (en) 2007-02-26 2010-11-30 The Chinese University Of Hong Kong Methods and kits for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer
US12180549B2 (en) 2007-07-23 2024-12-31 The Chinese University Of Hong Kong Diagnosing fetal chromosomal aneuploidy using genomic sequencing
EP3770275A1 (en) 2007-07-23 2021-01-27 The Chinese University of Hong Kong Determining a fetal aneuploidy
US20090053719A1 (en) 2007-08-03 2009-02-26 The Chinese University Of Hong Kong Analysis of nucleic acids by digital pcr
US8748100B2 (en) 2007-08-30 2014-06-10 The Chinese University Of Hong Kong Methods and kits for selectively amplifying, detecting or quantifying target DNA with specific end sequences
WO2009051842A2 (en) 2007-10-18 2009-04-23 The Johns Hopkins University Detection of cancer by measuring genomic copy number and strand length in cell-free dna
US20100041048A1 (en) 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
US8476013B2 (en) * 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
EP3751005A3 (en) 2008-09-20 2021-02-24 The Board of Trustees of the Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
WO2010053980A2 (en) 2008-11-04 2010-05-14 The Johns Hopkins University Dna integrity assay (dia) for cancer diagnostics, using confocal fluorescence spectroscopy
CN102369299A (zh) 2009-03-31 2012-03-07 奥里迪斯生物标记有限责任公司 用于癌症诊断和癌症治疗监测的方法
WO2011053790A2 (en) 2009-10-30 2011-05-05 Fluidigm Corporation Assay of closely linked targets in fetal diagnosis and coincidence detection assay for genetic analysis
CA2779695C (en) 2009-11-05 2016-05-24 The Chinese University Of Hong Kong Fetal genomic analysis from a maternal biological sample
EP2496713B1 (en) 2009-11-06 2018-07-18 The Chinese University of Hong Kong Size-based genomic analysis
US9260745B2 (en) 2010-01-19 2016-02-16 Verinata Health, Inc. Detecting and classifying copy number variation
US20120010085A1 (en) 2010-01-19 2012-01-12 Rava Richard P Methods for determining fraction of fetal nucleic acids in maternal samples
EP2536854B1 (en) * 2010-02-18 2017-07-19 The Johns Hopkins University Personalized tumor biomarkers
US10179937B2 (en) * 2014-04-21 2019-01-15 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20120053062A1 (en) * 2010-08-24 2012-03-01 Bio Dx, Inc. Defining diagnostic and therapeutic targets of conserved free floating fetal dna in maternal circulating blood
EP2426217A1 (en) 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
KR101891847B1 (ko) 2010-11-30 2018-08-24 더 차이니즈 유니버시티 오브 홍콩 암과 연관된 유전적 또는 분자적 이상들의 검출
WO2013043922A1 (en) 2011-09-22 2013-03-28 ImmuMetrix, LLC Compositions and methods for analyzing heterogeneous samples
US10196681B2 (en) 2011-10-06 2019-02-05 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP2771483A1 (en) 2011-10-25 2014-09-03 ONCOTYROL - Center for Personalized Cancer Medicine GmbH Method for diagnosing a disease based on plasma-dna distribution
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
JP6320302B2 (ja) 2012-01-27 2018-05-09 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 無細胞ｒｎａをプロファイリングおよび定量するための方法
HK1206055A1 (en) * 2012-03-02 2015-12-31 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
JP6411995B2 (ja) 2012-03-13 2018-10-24 ザ チャイニーズ ユニバーシティー オブ ホンコン 非侵襲的出生前診断のために大量並列シークエンシング・データを分析する方法
CA2874195C (en) * 2012-05-21 2020-08-25 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US20150105267A1 (en) * 2012-05-24 2015-04-16 University Of Washington Through Its Center For Commercialization Whole genome sequencing of a human fetus
US11261494B2 (en) * 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
US10041127B2 (en) 2012-09-04 2018-08-07 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
WO2014039729A1 (en) * 2012-09-05 2014-03-13 Stamatoyannopoulos John A Methods and compositions related to regulation of nucleic acids
US9732390B2 (en) 2012-09-20 2017-08-15 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma
FI3536807T3 (fi) 2012-09-20 2024-02-01 Univ Hong Kong Chinese Kasvaimen metylomin noninvasiivinen määritys plasmasta
KR102540202B1 (ko) * 2013-05-24 2023-06-02 시쿼넘, 인코포레이티드 유전적 변이의 비침습 평가를 위한 방법 및 프로세스
US20160115541A1 (en) * 2013-05-29 2016-04-28 Chronix Biomedical Detection and quantification of donor cell-free dna in the circulation of organ transplant recipients
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
EP3149199B1 (en) * 2014-05-30 2020-03-25 Verinata Health, Inc. Detecting, optionally fetal, sub-chromosomal aneuploidies and copy number variations
PT3543356T (pt) 2014-07-18 2021-10-04 Univ Hong Kong Chinese Análise dos padrões de metilação de tecidos em mistura de adn
KR102696857B1 (ko) 2014-07-25 2024-08-19 유니버시티 오브 워싱톤 무세포 dna를 생성하는 조직 및/또는 세포 유형을 결정하는 방법 및 이를 사용하여 질환 또는 장애를 확인하는 방법
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
US11242559B2 (en) 2015-01-13 2022-02-08 The Chinese University Of Hong Kong Method of nuclear DNA and mitochondrial DNA analysis
US10319463B2 (en) 2015-01-23 2019-06-11 The Chinese University Of Hong Kong Combined size- and count-based analysis of maternal plasma for detection of fetal subchromosomal aberrations
AU2016218631B2 (en) 2015-02-10 2022-03-10 The Chinese University Of Hong Kong Detecting mutations for cancer screening and fetal analysis
ES2960201T3 (es) 2015-07-23 2024-03-01 Univ Hong Kong Chinese Análisis de los patrones de fragmentación del ADN acelular

Also Published As

Publication number Publication date
CN107002122A (zh) 2017-08-01
AU2022202587A1 (en) 2022-05-26
EP3172341A2 (en) 2017-05-31
AU2015292311A1 (en) 2017-03-09
AU2015292311B2 (en) 2022-01-20
CA2956208A1 (en) 2016-01-28
US20210010081A1 (en) 2021-01-14
JP2021045161A (ja) 2021-03-25
WO2016015058A3 (en) 2016-03-17
KR102696857B1 (ko) 2024-08-19
EP3172341A4 (en) 2018-03-28
US20190127794A1 (en) 2019-05-02
US20230212672A1 (en) 2023-07-06
KR20220127359A (ko) 2022-09-19
KR20170044660A (ko) 2017-04-25
KR102441391B1 (ko) 2022-09-07
US20170211143A1 (en) 2017-07-27
JP7681641B2 (ja) 2025-05-22
WO2016015058A2 (en) 2016-01-28
JP2023123420A (ja) 2023-09-05
US11352670B2 (en) 2022-06-07
JP2017522908A (ja) 2017-08-17
CN107002122B (zh) 2023-09-19
CN117402950A (zh) 2024-01-16
AU2022202587B2 (en) 2024-07-04
EP4358097A1 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
JP7681641B2 (ja) セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法
Liu At the dawn: cell-free DNA fragmentomics and gene regulation
Snyder et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin
JP6829211B2 (ja) 癌スクリーニング及び胎児分析のための変異検出
US20190309352A1 (en) Multimodal assay for detecting nucleic acid aberrations
CN105518151A (zh) 循环核酸肿瘤标志物的鉴别和用途
RU2018121254A (ru) Высокоэффективное построение библиотек днк
EP3526350B1 (en) Determining cell type origin of circulating cell-free dna with molecular counting
EP3555311B1 (en) Determining a physiological condition in an individual by analyzing cell-free dna fragment endpoints in a biological sample
CN105793438B (zh) 未知序列的双股线性核酸的全长扩增方法
US20200255905A1 (en) Diagnosis of cancer or other physiological condition using circulating nucleic acid fragment sentinel endpoints
HK40110787A (en) Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
CN108796056A (zh) 基于游离dna的目标基因捕获技术进行组织溯源的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200721

EEER Examination request

Effective date: 20200721

EEER Examination request

Effective date: 20200721

EEER Examination request

Effective date: 20200721

EEER Examination request

Effective date: 20200721

EEER Examination request

Effective date: 20200721

EEER Examination request

Effective date: 20200721

EEER Examination request

Effective date: 20200721

EEER Examination request

Effective date: 20200721